Elranatamab Phase 3 Trial for Multiple Myeloma Reaches Primary Completion

The Phase 3 study (NCT05020236) investigating elranatamab for people with multiple myeloma reached its primary completion on 2026-04-27. This trial is designed to assess elranatamab alone and in combination with daratumumab against a standard combination therapy.

Background

The study, titled "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments," focuses on individuals with multiple myeloma who have previously received other treatments, including lenalidomide. Elranatamab is a BCMA-CD3 bispecific antibody, while daratumumab is an anti-CD38 monoclonal antibody, both relevant in the treatment landscape for multiple myeloma.

Trial design

The Phase 3 clinical trial (NCT05020236) is currently RECRUITING and has an estimated enrollment of 944 participants. The study is designed to evaluate elranatamab as a potential treatment for multiple myeloma. One primary objective is to determine if elranatamab can offer greater benefit compared to a combination therapy that includes daratumumab, pomalidomide, and dexamethasone. Additionally, the trial aims to assess the safety and activity of elranatamab when administered in combination with daratumumab.

What this means

The primary completion of this Phase 3 trial for elranatamab in multiple myeloma marks a significant milestone in its development. This stage indicates that the study has completed its planned data collection for its primary objectives, moving closer to potential analysis and reporting of results. For clinicians and patients, the progression of such a large-scale trial suggests ongoing efforts to bring new therapeutic options to those living with previously treated multiple myeloma.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05020236, titled "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments," was noted with a primary completion date of 2026-04-27 on clinicaltrials.gov.